AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in Vaccine Research
News Aug 09, 2011
MorphoSys AG has announced that its research and diagnostic antibody unit AbD Serotec has amended its existing license agreement with Merck & Co., Inc. to include the use of MorphoSys's HuCAL GOLD technology in the field of vaccines.
Under the terms of the agreement, Merck is granted access to HuCAL GOLD for research purposes, with the option to upgrade to MorphoSys's latest proprietary antibody library HuCAL PLATINUM.
MorphoSys's research and diagnostic antibody segment AbD Serotec will receive annual user fees from Merck for access to the HuCAL technology and license fees for clinical monitoring reagents. Further financial details were not disclosed.
"We welcome Merck's decision to continue using the HuCAL technology on the research side as a tool to support their vaccine development activities. It is a clear sign of the sustained interest of the pharmaceutical industry in our leading antibody technology," commented Dieter Feger, Senior Vice President and Head of AbD Serotec.
Almost 95% of people with early-diagnosed breast cancer will require surgery and it’s often the first line of treatment for people with brain tumors, for example. But despite improvements in surgical techniques over the past decade, the cancer often comes back after the procedure. Now, a team has developed a spray gel embedded with immune-boosting drugs that could help.READ MORE
23rd World Congress on Pediatrics, Neonatology & Primary Care
Nov 22 - Nov 23, 2019